Literature DB >> 26769253

Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration.

Caitlin M Kirkwood, Matthew L MacDonald, Tadhg A Schempf, Anil V Vatsavayi, Milos D Ikonomovic, Jeremy L Koppel, Ying Ding, Mai Sun, Julia K Kofler, Oscar L Lopez, Nathan A Yates, Robert A Sweet.   

Abstract

Recent studies have implicated the neuronal calcium-sensing protein visinin-like 1 protein (Vilip-1) as a peripheral biomarker in Alzheimer disease (AD), but little is known about expression of Vilip-1 in the brains of patients with AD. We used targeted and quantitative mass spectrometry to measure Vilip-1 peptide levels in the entorhinal cortex (ERC) and the superior frontal gyrus (SF) from cases with early to moderate stage AD, frontotemporal lobar degeneration (FTLD), and cognitively and neuropathologically normal elderly controls. We found that Vilip-1 levels were significantly lower in the ERC, but not in SF, of AD subjects compared to normal controls. In FTLD cases, Vilip-1 levels in the SF were significantly lower than in normal controls. These findings suggest a unique role for cerebrospinal fluid Vilip-1 as a biomarker of ERC neuron loss in AD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26769253      PMCID: PMC5943680          DOI: 10.1093/jnen/nlv018

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  41 in total

1.  CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.

Authors:  Xinni Luo; Le Hou; Haishan Shi; Xiaomei Zhong; Yufeng Zhang; Dong Zheng; Yan Tan; Guoyan Hu; Nan Mu; Jianping Chan; Xinru Chen; Yaxiu Fang; Fengchun Wu; Hongbo He; Yuping Ning
Journal:  J Neurochem       Date:  2013-06-26       Impact factor: 5.372

2.  Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

3.  The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease?

Authors:  I Schnurra; H G Bernstein; P Riederer; K H Braunewell
Journal:  Neurobiol Dis       Date:  2001-10       Impact factor: 5.996

4.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB.

Authors:  S M Resnick; J Sojkova; Y Zhou; Y An; W Ye; D P Holt; R F Dannals; C A Mathis; W E Klunk; L Ferrucci; M A Kraut; D F Wong
Journal:  Neurology       Date:  2010-02-10       Impact factor: 9.910

5.  Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer's disease.

Authors:  T Bussière; G Gold; E Kövari; P Giannakopoulos; C Bouras; D P Perl; J H Morrison; P R Hof
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

6.  The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients.

Authors:  Jin-Moo Lee; Kaj Blennow; Niels Andreasen; Omar Laterza; Vijay Modur; Jitka Olander; Feng Gao; Matt Ohlendorf; Jack H Ladenson
Journal:  Clin Chem       Date:  2008-08-14       Impact factor: 8.327

7.  Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations.

Authors:  Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2008-11-18       Impact factor: 17.088

Review 8.  The MAP2/Tau family of microtubule-associated proteins.

Authors:  Leif Dehmelt; Shelley Halpain
Journal:  Genome Biol       Date:  2004-12-23       Impact factor: 13.583

9.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

10.  VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.

Authors:  Chien-Wei Lin; Lun-Ching Chang; George C Tseng; Caitlin M Kirkwood; Etienne L Sibille; Robert A Sweet
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

View more
  9 in total

1.  Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease.

Authors:  Robert A Sweet; Matthew L MacDonald; Caitlin M Kirkwood; Ying Ding; Tadhg Schempf; Jackie Jones-Laughner; Julia Kofler; Milos D Ikonomovic; Oscar L Lopez; Megan E Garver; Nicholas F Fitz; Radosveta Koldamova; Nathan A Yates
Journal:  Mol Cell Proteomics       Date:  2016-04-21       Impact factor: 5.911

Review 2.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

Review 3.  Calcium Sensors in Neuronal Function and Dysfunction.

Authors:  Robert D Burgoyne; Nordine Helassa; Hannah V McCue; Lee P Haynes
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-05-01       Impact factor: 10.005

Review 4.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

5.  Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.

Authors:  Alejandro López-Hurtado; Daniel F Burgos; Paz González; Xose M Dopazo; Valentina González; Alberto Rábano; Britt Mellström; Jose R Naranjo
Journal:  Mol Brain       Date:  2018-03-09       Impact factor: 4.041

6.  VSNL1 Promotes Gastric Cancer Cell Proliferation and Migration by Regulating P2X3/P2Y2 Receptors and Is a Clinical Indicator of Poor Prognosis in Gastric Cancer Patients.

Authors:  Qiao-Qiong Dai; Yuan-Yu Wang; Yu-Peng Jiang; Li Li; Hui-Ju Wang
Journal:  Gastroenterol Res Pract       Date:  2020-12-09       Impact factor: 2.260

7.  Broad Kinase Inhibition Mitigates Early Neuronal Dysfunction in Tauopathy.

Authors:  Shon A Koren; Matthew J Hamm; Ryan Cloyd; Sarah N Fontaine; Emad Chishti; Chiara Lanzillotta; Jennifer Rodriguez-Rivera; Alexandria Ingram; Michelle Bell; Sara M Galvis-Escobar; Nicholas Zulia; Fabio Di Domenico; Duc Duong; Nicholas T Seyfried; David Powell; Moriel Vandsburger; Tal Frolinger; Anika M S Hartz; John Koren; Jeffrey M Axten; Nicholas J Laping; Jose F Abisambra
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

8.  Psychosis in Alzheimer's Disease Is Associated With Increased Excitatory Neuron Vulnerability and Post-transcriptional Mechanisms Altering Synaptic Protein Levels.

Authors:  Michael R DeChellis-Marks; Yue Wei; Ying Ding; Cody M Wolfe; Joshua M Krivinko; Matthew L MacDonald; Oscar L Lopez; Robert A Sweet; Julia Kofler
Journal:  Front Neurol       Date:  2022-03-02       Impact factor: 4.003

9.  Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice.

Authors:  Joseph Flores; Marie-Lyne Fillion; Andréa C LeBlanc
Journal:  Cell Death Dis       Date:  2022-10-11       Impact factor: 9.685

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.